Want to see JP:4598 full AI Analyst Report?
Delta-Fly Pharma, Inc. (4598) AI Stock Analysis
Delta-Fly Pharma, Inc.
(TSE/TYO:4598)
Delta-Fly Pharma's score reflects its highly speculative status as an early-stage biotechnology company. The most significant risks are its severe cash burn, rapidly deteriorating equity base, and deeply negative earnings. These fundamental weaknesses are further compounded by a heavily bearish technical downtrend, reflecting significant market pessimism and a likely need for dilutive external financing.
Delta-Fly Pharma, Inc. (4598) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 981.51M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.32M
- Price to Earnings (P/E)
- -0.5
- Beta (1Y)
- 0.30
- Revenue Growth
- ―
- EPS Growth
- 20.94%
- Country
- Japan
- Employees
- 12
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Delta-Fly Pharma, Inc. Business Overview & Revenue Model
Company Description
Delta-Fly Pharma, Inc., established in Tokushima, Japan, in 2010, is a biotechnology company focused on the development of innovative oncology drugs. Their comprehensive pipeline includes several drug candidates targeting various cancers. DFP-10917 i...
Delta-Fly Pharma, Inc. Financial Statement Overview
Summary
The company exhibits a highly speculative profile with zero revenue, substantial net losses, and massive cash burn. Despite carrying no debt, the rapidly shrinking equity base creates a high risk of imminent shareholder dilution to fund ongoing operations.
Income Statement
10Very NegativeBalance Sheet
25NegativeCash Flow
10Very Negative| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 300.00M |
| Gross Profit | -1.55M | -1.59M | -1.44M | -1.51M | -1.63M | 300.00M |
| EBITDA | -1.57B | -1.71B | -1.60B | -1.40B | -1.31B | -959.79M |
| Net Income | -1.59B | -1.72B | -1.63B | -1.43B | -1.33B | -967.30M |
Balance Sheet | ||||||
| Total Assets | 790.57M | 434.33M | 246.67M | 1.47B | 906.82M | 1.32B |
| Cash, Cash Equivalents and Short-Term Investments | 730.32M | 338.83M | 145.45M | 1.42B | 844.34M | 1.27B |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 137.03M | 156.54M | 212.69M | 241.50M | 115.62M | 91.19M |
| Stockholders Equity | 653.55M | 277.80M | 33.98M | 1.23B | 791.20M | 1.23B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -1.83B | -1.56B | -1.28B | -1.30B | -940.40M |
| Operating Cash Flow | 0 | -1.83B | -1.56B | -1.28B | -1.30B | -940.40M |
| Investing Cash Flow | 0 | -206.00K | 0 | 207.00K | -326.00K | 0 |
| Financing Cash Flow | 0 | 756.70M | 1.36B | 1.85B | 882.62M | 119.86M |
Delta-Fly Pharma, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4598, the sentiment is Negative. The current price of 68.00 is below the 20-day moving average (MA) of 86.50, below the 50-day MA of 102.90, and below the 200-day MA of 167.38, indicating a bearish trend. The MACD of -10.40 indicates Positive momentum. The RSI at 25.34 is Positive, neither overbought nor oversold. The STOCH value of 21.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4598.
Delta-Fly Pharma, Inc. Peers Comparison
Overall Rating
JP:458855Neutral
JP:459243Neutral
JP:459142Neutral
JP:458741.5Neutral- JP:459838Underperform
JP:456331Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4588 | 55Neutral | JPY 223.32B | -137.55 | ― | ― | 1662.38% | 42.86% |
| JP:4592 | 43Neutral | JPY 71.58B | -19.22 | -37.79% | ― | ― | 5.71% |
| JP:4591 | 42Neutral | JPY 3.64B | -2.80 | ― | ― | 1135.58% | 2.37% |
| JP:4587 | 42Neutral | JPY 145.02B | -39.74 | -7.17% | ― | 0.62% | 27.66% |
| JP:4598 | 38Underperform | JPY 1.33B | -0.51 | ― | ― | ― | 20.94% |
| JP:4563 | 31Underperform | JPY 11.75B | -3.04 | -163.39% | ― | 35.28% | 90.12% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4598 | Delta-Fly Pharma, Inc. | 69.00 | -350.00 | -83.53% | |
| JP:4563 | AnGes | 29.00 | -57.00 | -66.28% | |
| JP:4587 | Peptidream | 1117.00 | -414.00 | -27.04% | |
| JP:4592 | SanBio Co | 917.00 | -1928.00 | -67.77% | |
| JP:4588 | Oncolys BioPharma, Inc. | 7560.00 | 6795.00 | 888.24% | |
| JP:4591 | Ribomic, Inc. | 64.00 | -27.00 | -29.67% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 23, 2026